PSMA PET\/CT scans predict progression-free survival and guide personalized treatment strategies for recurring prostate cancer.<\/p>\n
Researchers at the University of California, Los Angeles (UCLA, CA, USA) have reported insights into the role of prostate-specific membrane antigen (PSMA) PET\/CT scans in guiding treatment for prostate cancer patients with rising prostate-specific antigen (PSA) levels following after radical prostatectomy. Led by John Nikitas and published in the latest issue of\u00a0JNCCN<\/a>, the study highlights PSMA PET\/CT\u2019s ability to refine treatment strategies for recurrent prostate cancer.<\/p>\n The challenge of prostate cancer recurrence<\/p>\n Prostate cancer is the second most common cancer in men, with 20\u201340% of patients experiencing biochemical recurrence within 10 years of radical prostatectomy. Salvage radiotherapy (sRT) to the prostate bed is the standard treatment and is recommended when prostate-specific antigen (PSA) levels are 0.1 to 0.2. However, conventional imaging modalities, such as CT and MRI, have limited sensitivity for detecting recurrent disease at low PSA levels (<1 ng\/mL), often leading to generalized treatment approaches. PSMA PET\/CT offers enhanced sensitivity, enabling precise targeting of PSMA-avid disease and more personalized therapy.<\/p>\n Key study results<\/p>\n This study analyzed data from 113 patients treated at the \u00a0UCLA Jonsson Comprehensive Cancer Center between 2016 and 2021. All patients underwent PSMA PET\/CT scans within 3 months of undergoing sRT and had at least 24 months of follow-up. The results were striking: patients with no visible disease (T0N0M0) had the most favorable progression-free survival (PFS), with whole-pelvis radiotherapy showing no significant benefit compared to prostate bed radiotherapy alone. Whereas those with local visible disease (TrN0M0) benefited significantly from whole-pelvis radiotherapy. For patients with nodal or distant metastases (N1\/M1), androgen deprivation therapy (ADT) was associated with improved PFS.<\/p>\n \u201cPSMA PET\/CT allows us to move beyond one-size-fits-all radiation therapy to treatment tailored to the anatomy and biology of each patient\u2019s cancer,\u201d explained Nikitas. \u201cThis approach not only improves outcomes but also reduces unnecessary side effects.\u201d<\/p>\n Potential clinical impact<\/p>\n The 5-year outcomes underscore the impact of PSMA PET\/CT-guided sRT. At 5 years, approximately three-quarters of patients were free from distant metastasis (72.4%), and nearly all were alive (overall survival was 97.1% at 5 years). Despite its promise, the study highlights challenges in accessibility and implementation. PSMA PET\/CT scans are not yet universally available, and their integration into clinical practice requires significant resources.<\/p>\n \u201cThis research highlights the importance of facilitating routine PSMA PET\/CT scans in patients with a biochemical recurrence of prostate cancer after surgery to remove the prostate gland,\u201d said Nikitas. \u201cThe information from these scans is strongly associated with long-term outcomes and frequently changes treatment recommendations. We found that other measures, like PSA levels, were\u00a0not strongly associated with long-term response to secondary\/salvage therapy.\u201d<\/p>\n Expert commentary on the treatment landscape<\/p>\n